Spin-offs

Omne Possibile

Omne Possibile

Omne possibile was founded in March 2021. The company focuses on realizing the potential of XNA technologies in modern biotechnology, relying on metabolic engineering and xenobiotic import strategies developed at the BPL.

Contact

Omne possibile
c/o BPL, D-BSSE ETHZ
Mattenstrasse 26
4058 Basel
Schweiz

MemoTherapeutics

MemoTherapeutics

MemoTherapeutics was founded in 2013. The company focuses on the clinical development of antibodies. The Bioprocess Laboratory developed the first generation of high throughput screening protocols employed by MemoTherapeutics for antibody discovery.

Contact

MemoTherapeutics AG
Bio-Technopark Schlieren
Wagistrasse 27
8952 Schlieren
Schweiz

FGen

FGen

FGen was founded in 2012. The company operates as a custom research partner for the pharmaceutical and chemical industry. The startup technology of FGen is the nanoliter reactor platform for high throughput screening in gel-carriers originally developed by the Bioprocess Laboratory.

Contact

FGen GmbH
Hochbergerstrasse 60C
4057 Basel
Schweiz

JavaScript has been disabled in your browser